Facts about CaviWipes and SARS-COV-2 (novel coronavirus)

Protocols for Disinfection Efficacy on COVID-19
As of the date of this writing, there is currently no EPA recognized test protocol to evaluate disinfection efficacy against this specific novel coronavirus virus strain, SARS-COV-2 (Severe Acute Respiratory Syndrome Coronavirus 2), which causes COVID-19 (Coronavirus Disease 2019). Therefore, there is no EPA-registered surface disinfectant that bares a label claim against SARS-COV-2 as of the date of this writing.

CDC recommends using products with EPA-approved emerging viral pathogens claims against COVID-19. If an EPA-registered disinfectant with the Emerging Viral Pathogen claim is not available, products with the label claim against Human Coronavirus should be used according to the label instructions.

CaviCide and CaviWipes Efficacy Regarding Coronavirus
CaviCide, which is the solution used to impregnate CaviWipes, has an EPA-registered label claim against Human Coronavirus.

Metrex has recently performed an efficacy study on CaviWipes against the SARS-CoV (SARS-associated Human Coronavirus) in a third-party test lab. According to the study report, the study results passed the Viricidal Hard Surface Efficacy Test by exceeding a 3-log/99.9% reduction of the virus. However, this study result has not yet been reviewed or approved by the US EPA. CaviWipes does not have an Emerging Viral Pathogen claim, nor a labelling claim against Human Coronavirus.

Even though SARS-CoV, Human Coronavirus, and SARS-COV-2 are not the same virus strains, all coronavirus strains are enveloped viral particles that belong to the same virus family of Coronaviridae. Enveloped viral particles are typically more susceptible to chemical disinfectant formulations than are other common pathogens.

REFERENCES: